Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and Vorinostat in Relapsed/Refractory and/or Metastatic Breast Cancer
NCT03742245Phase 1Active, not recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Jun 2019
- Primary completion
- Dec 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olaparib and vorinostat in breast cancer, sponsored by Houston Methodist Research Institute. Primary endpoint: Maximum Tolerated Dose at 16 weeks. Started Jun 2019; status: active, not recruiting.
02
Drugs
olaparibvorinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03742245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03742245.